Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 6 (2009), Issue 2 (February)

1. Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma.
   Am J Obstet Gynecol, 200(2): 175.e1-5. [Abstract] [Full-text]
2. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status.
   Am J Obstet Gynecol, 200(2): 182.e1-5. [Abstract] [Full-text]
3. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.
   Gastroenterology, 136(2): 451-8. [Abstract] [Full-text]
4. Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo.
   Toxicology, 257(1): 80-5. [Abstract] [Full-text]
5. Optimized dose distribution of Gammamed plus vaginal cylinders.
   Med Dosim, 34(1): 20-5. [Abstract] [Full-text]
6. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells.
   Cancer Immunol Immunother, 58(4): 603-14. [Abstract] [Full-text]
7. Different cervical cancer screening approaches in a Chinese multicentre study.
   Br J Cancer, 100(3): 532-7. [Abstract] [Full-text]
8. Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical cancer.
   J Clin Microbiol, 47(2): 287-93. [Abstract] [Full-text]
9. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
   Oncogene, 28(5): 762-72. [Abstract] [Full-text]
10. CMTM5-v1 induces apoptosis in cervical carcinoma cells.
    Biochem Biophys Res Commun, 379(4): 866-71. [Abstract] [Full-text]
11. Transition of cervical carcinoma in situ to invasive cancer: role of p16 INK4a expression in progression and in recurrence.
    Exp Mol Pathol, 86(1): 46-50. [Abstract] [Full-text]
12. PMMA particle-mediated DNA vaccine for cervical cancer.
    J Biomed Mater Res A, 88(4): 849-57. [Abstract] [Full-text]
13. Papillomaviruses in the causation of human cancers - a brief historical account.
    Virology, 384(2): 260-5. [Abstract] [Full-text]
14. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks.
    Am J Epidemiol, 169(4): 480-8. [Abstract] [Full-text]
15. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma.
    Virology, 384(2): 375-9. [Abstract] [Full-text]
16. Effect of bladder distention on bladder base dose in gynaecological intracavitary high dose rate brachytherapy.
    Br J Radiol, 82(975): 243-8. [Abstract] [Full-text]
17. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging.
    Int J Radiat Oncol Biol Phys, 73(3): 838-45. [Abstract] [Full-text]
18. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.
    Int J Cancer, 124(8): 1829-40. [Abstract] [Full-text]
19. MRI and PET/CT for triaging stage IB clinically operable cervical cancer to appropriate therapy: decision analysis to assess patient outcomes.
    AJR Am J Roentgenol, 192(3): 802-14. [Abstract] [Full-text]
20. Estrogen formation in endometrial and cervix cancer cell lines: involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12).
    Mol Cell Endocrinol, 301(1): 142-5. [Abstract] [Full-text]
21. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix.
    Arch Gynecol Obstet, 279(4): 521-5. [Abstract] [Full-text]
22. Primary malignant melanoma of the cervix: report of a case.
    Arch Gynecol Obstet, 279(4): 573-5. [Abstract] [Full-text]
23. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program.
    Gynecol Oncol, 112(3): 572-6. [Abstract] [Full-text]
24. Abdominal radical trachelectomy: Success and pitfalls in a general gynecologic oncology practice.
    Gynecol Oncol, 112(3): 506-10. [Abstract] [Full-text]
25. Intraoperative gross assessment of myometrial invasion and cervical involvement in endometrial cancer: Role of tumor grade and size.
    Gynecol Oncol, 112(3): 517-20. [Abstract] [Full-text]
26. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
    Gynecol Oncol, 112(3): 583-9. [Abstract] [Full-text]
27. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy.
    Gynecol Oncol, 112(3): 590-3. [Abstract] [Full-text]
28. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.
    Gynecol Oncol, 112(3): 646-53. [Abstract] [Full-text]

© 2004-2010 Cervical Cancer Research Today. All Rights Reserved.